Want to see IN:RPGLIFE full AI Analyst Report?
Top Page
RPG Life Sciences Limited
(RPGLIFE)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹3,352.00
â–²(15.07% Upside)
Action:Reiterated
Date:09/24/26
The score is supported mainly by a high-quality, low-debt balance sheet and strong technical uptrend. It is held back by FY2026 margin compression and a notable weakening in cash-flow conversion (including slightly negative free cash flow), plus a relatively expensive valuation (high P/E and low dividend yield).
Positive Factors
Very low leverage
A conservatively positioned balance sheet gives RPG Life Sciences substantial financial flexibility and limits balance-sheet risk. Low leverage can support continued investment in branded formulations, help absorb earnings volatility, and reduce the burden of debt service over the next several quarters.
Negative Factors
FY2026 margin compression
The sharp FY2026 margin deterioration weakens the near-term quality and predictability of earnings, even though revenue continues to grow. If margins remain below prior levels, less revenue will convert into profit, limiting internal reinvestment capacity and reducing operating resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
A conservatively positioned balance sheet gives RPG Life Sciences substantial financial flexibility and limits balance-sheet risk. Low leverage can support continued investment in branded formulations, help absorb earnings volatility, and reduce the burden of debt service over the next several quarters.
Read all positive factors
RPG Life Sciences Limited (RPGLIFE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹47.94B
Dividend Yield0.79%
Average Volume (3M)1.15K
Price to Earnings (P/E)42.2
Beta (1Y)0.80
Revenue Growth11.78%
EPS Growth-34.54%
CountryIN
Employees1,366
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)72.34
Shares Outstanding16,539,015
10 Day Avg. Volume1,395
30 Day Avg. Volume1,150
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)5.08
Price to Sales (P/S)4.34
P/FCF Ratio-38.40K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RPG Life Sciences Limited Business Overview & Revenue Model
Company Description
RPG Life Sciences Limited operates as a fully integrated pharmaceutical enterprise, engaged in the development, production, and commercialization of branded drug formulations, generic medications, and synthetic active pharmaceutical ingredients (A...
How the Company Makes Money
RPGLIFE makes money primarily by selling pharmaceutical formulations (finished dosage medicines) under its own brands. Revenue is generated when the company manufactures (in-house and/or through third-party contract manufacturing, where applicable...
RPG Life Sciences Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.34B | 7.08B | 6.53B | 5.77B | 5.09B | 4.37B |
| Gross Profit | 3.06B | 2.92B | 4.39B | 3.93B | 1.70B | 2.87B |
| EBITDA | 1.84B | 1.77B | 1.60B | 1.36B | 1.08B | 902.40M |
| Net Income | 1.20B | 1.15B | 1.83B | 876.60M | 676.40M | 514.80M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 7.93B | 6.58B | 5.13B | 4.19B | 3.45B |
| Cash, Cash Equivalents and Short-Term Investments | 2.74B | 2.75B | 2.66B | 1.26B | 1.15B | 698.00M |
| Total Debt | 0.00 | 200.00M | 0.00 | 0.00 | 100.00K | 9.40M |
| Total Liabilities | -6.05B | 1.88B | 1.27B | 1.38B | 1.12B | 888.40M |
| Stockholders Equity | 6.05B | 6.05B | 5.31B | 3.75B | 3.08B | 2.56B |
Cash Flow | ||||||
| Free Cash Flow | -207.00M | -800.00K | 418.30M | 251.30M | 580.90M | 408.00M |
| Operating Cash Flow | 112.70M | 652.80M | 778.60M | 943.60M | 908.20M | 647.50M |
| Investing Cash Flow | 206.70M | 761.70M | -418.00M | -791.50M | -1.06B | -346.60M |
| Financing Cash Flow | -399.40M | -196.90M | -270.80M | -203.10M | -171.20M | -135.10M |
RPG Life Sciences Limited Technical Analysis
Positive
2913.00
Price Trends
2752.71
Positive
2543.18
Positive
2297.71
Positive
Market Momentum
69.43
Negative
64.45
Neutral
80.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:RPGLIFE, the sentiment is Positive. The current price of 2913 is above the 20-day moving average (MA) of 2750.79, above the 50-day MA of 2752.71, and above the 200-day MA of 2297.71, indicating a bullish trend. The MACD of 69.43 indicates Negative momentum. The RSI at 64.45 is Neutral, neither overbought nor oversold. The STOCH value of 80.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:RPGLIFE.
RPG Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹72.89B | 55.14 | ― | 0.21% | 20.59% | 27.16% | |
71 Outperform | ₹47.94B | 42.17 | ― | 0.79% | 11.78% | -34.54% | |
64 Neutral | ₹59.82B | 35.70 | ― | 0.49% | 18.56% | 60.06% | |
57 Neutral | ₹39.00B | 12.70 | ― | 1.34% | 9.43% | 132.94% | |
56 Neutral | ₹26.41B | -79.41 | ― | 0.28% | -5.37% | -153.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹35.01B | -1,319.91 | ― | 0.45% | 15.49% | -112.78% |
* General Sector Average
IN:RPGLIFE
RPG Life Sciences Limited
3,036.10
755.24
33.11%
IN:BLISSGVS
Bliss Gvs Pharma Limited
709.30
564.80
390.85%
IN:HIKAL
Hikal Limited
217.95
-36.18
-14.24%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
204.25
101.77
99.31%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
737.15
120.30
19.50%
IN:UNICHEMLAB
Unichem Laboratories Limited
550.20
71.50
14.94%
RPG Life Sciences Limited Corporate Events
RPG Life Sciences Completes Acquisition of API Business via Slump Sale
Sep 15, 2026
RPG Life Sciences has announced that its subsidiary RPG Active Pharma Limited has completed the business transfer agreement with Raghava Life Sciences Private Limited for the acquisition of active pharmaceutical ingredients and intermediates busin...
RPG Life Sciences Posts Analyst Call Recording for Investor Access
Sep 4, 2026
RPG Life Sciences Limited has informed the stock exchanges that the recording and related details of its analyst and institutional investor call held on September 3, 2026 are now available on the company’s website for public access. The disc...
RPG Life Sciences to Brief Investors on API Business in Scheduled Conference Call
Sep 3, 2026
RPG Life Sciences Limited has scheduled an analyst and institutional investor conference call to provide an update on its API business, with senior management, including the managing director and chief financial officer, set to address participant...
RPG Life Sciences Circulates Investor Presentation on Active Pharma Transaction
Sep 2, 2026
RPG Life Sciences Limited has notified India’s major stock exchanges that it has prepared an investor presentation for analysts and institutional investors. The company, which operates in the pharmaceutical sector and is listed on NSE and BS...
RPG Life Sciences Cancels Scheduled Investor and Analyst Meet
Sep 1, 2026
RPG Life Sciences Limited has announced that its previously scheduled investors and analysts meeting, which was to be held on Wednesday, September 2, 2026, at 10:00 a.m., has been cancelled. The company informed the stock exchanges in compliance w...
RPG Life Sciences injects Rs 65.69 crore into wholly owned pharma subsidiary
Aug 14, 2026
RPG Life Sciences Limited has invested up to Rs 65.69 crore in its wholly owned subsidiary, RPG Active Pharma Limited through a rights issue of equity shares. Following the allotment of 21,89,535 shares on August 14, 2026, RPG Life Sciences’...
RPG Life Sciences Completes Transfer of API Business to Subsidiary
Aug 14, 2026
RPG Life Sciences Limited has completed the transfer of its active pharmaceutical ingredients business to RPG Active Pharma Limited, a wholly owned subsidiary, under a business transfer agreement executed on a slump sale basis. The transaction, ef...
RPG Life Sciences Moves API Chief to Lead Subsidiary RPG Active Pharma
Aug 14, 2026
RPG Life Sciences Limited has announced a key change in its senior management, centered on its API operations and subsidiary governance. The move reflects the company’s practice of aligning leadership roles with its multi-entity pharmaceutic...
RPG Life Sciences to Join Emkay Confluence 2026 Investor Meet
Aug 10, 2026
RPG Life Sciences Limited has informed the stock exchanges that it will participate in the Emkay Confluence 2026, an analyst and institutional investors meet scheduled in Mumbai on August 13, 2026, starting at 9:00 a.m. IST. The session will be a ...
RPG Life Sciences Discloses Retirement of Senior Sales and Marketing Executive
Jul 31, 2026
RPG Life Sciences Limited has announced that Mr. Samir Rane, Vice President, Sales Marketing – Main Division, has retired upon attaining the age of superannuation and consequently ceased to be part of the company’s senior management. ...
RPG Life Sciences Restructures API Business, Sets Up New Investment Platform
Jul 29, 2026
RPG Life Sciences’ board has approved the transfer of its active pharmaceutical ingredients business to wholly owned subsidiary RPG Active Pharma Limited, as a going concern on a slump sale basis, for about Rs. 33.55 crore, with completion t...
RPG Life Sciences Spins Off API Unit to Subsidiary, Plans Investment-Led Expansion
Jul 29, 2026
RPG Life Sciences Limited has approved the transfer of its active pharmaceutical ingredients business to its wholly owned subsidiary RPG Active Pharma Limited via a slump sale, valuing the unit at about Rs. 33.55 crore. The API business, which acc...
RPG Life Sciences Restructures API Business, Subsidiary to Acquire Actis Generics
Jul 29, 2026
RPG Life Sciences Limited, a diversified pharmaceutical company, derives a meaningful share of its turnover and net worth from its active pharmaceutical ingredients business, which serves domestic and international healthcare markets. The API unit...
RPG Life Sciences Spins Off API Unit, Secures PE Funding and Actis Generics Deal
Jul 29, 2026
RPG Life Sciences has approved the transfer of its active pharmaceutical ingredients business to wholly owned subsidiary RPG Active Pharma on a slump sale basis, creating a focused platform for API growth alongside its existing formulations operat...
RPG Life Sciences Reshapes Sustainability Committee After Independent Director’s Tenure Ends
Jul 27, 2026
RPG Life Sciences Limited has announced that Independent Director Ms. Zahabiya Khorakiwala’s second consecutive five-year term concluded on July 26, 2026, resulting in her cessation from the board. Following the end of her tenure, she will n...
RPG Life Sciences Clears All Resolutions at 19th AGM Conducted via E-Voting
Jul 23, 2026
RPG Life Sciences Limited held its nineteenth annual general meeting on July 23, 2026 via video conferencing, in compliance with Ministry of Corporate Affairs and SEBI norms. The meeting was chaired by Harsh V. Goenka, with key board members, stat...
RPG Life Sciences Secures Shareholder Approval on All AGM Resolutions
Jul 23, 2026
RPG Life Sciences Limited held its nineteenth annual general meeting on July 23, 2026 via video conferencing, in compliance with MCA and SEBI guidelines and the Companies Act. The meeting was chaired by Harsh V. Goenka, with key board members and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.